New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
06:38 EDTFRX, GS, ACT, MSMorgan Stanley, Goldman said to switch fees for deal credit, Bloomberg says
Morgan Stanley (MS) and Goldman Sachs (GS) both decided last month that it was worth losing millions of dollars in fees to get credit on the $25B sale of Forest Laboratories (FRX) to Actavis (ACT), according to Bloomberg, citing four people with knowledge of the matter. The sources say that neither investment bank actually had a role on the deal. Reference Link
News For MS;GS;FRX;ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 13, 2015
16:37 EDTACTActavis announces availability of 52mg Liletta to prevent pregnancy
Actavis and Medicines360, a nonprofit women's health pharmaceutical company, announced that Liletta 52 mg is now available in the U.S. for use by women to prevent pregnancy for up to three years.
10:52 EDTACTMeister says Actavis bought great companies, can continue growing
Subscribe for More Information
09:27 EDTACTActavis and Medicine360 announce Liletta es available in the U.S.
Subscribe for More Information
08:42 EDTGSPandora rises after Spotify reportedly valued above $8B in fundraising
Subscribe for More Information
08:34 EDTACTZoetis names Actavis Executive Chairman Paul Bisaro to board
Subscribe for More Information
07:52 EDTMSPotential rule change on accounts to likely be manageable, says JMP Securities
Subscribe for More Information
07:16 EDTMSTechWeek to hold a conference
TechWeek Detroit 2015 is being held in Detroit on 4/13-19.
06:39 EDTGSGoldman Sachs in talks to sell NPL business of Archon to D.E. Shaw, Reuters says
Subscribe for More Information
April 10, 2015
17:26 EDTGSSpotify close to deal to raise $400M, WSJ reports
Subscribe for More Information
April 9, 2015
11:39 EDTACTPershing Square, Valeant, Allergan drop lawsuit over buyout
Subscribe for More Information
07:17 EDTGSGoldman Sachs April volatility elevated into Q1 and outlook
Goldman Sachs April call option implied volatility is at 24, May is at 19, July is at 18; compared to its 26-week average of 20 according to Track Data, suggesting large near term price movement into the expected release of Q1 results on April 16.
April 8, 2015
12:36 EDTGSGoogle, Facebook not discussing Twitter buyout, Re/code reports
Subscribe for More Information
10:26 EDTGSBofA Merill Lynch names De Giorgi, Assef as investment banking co-heads, FT says
Subscribe for More Information
09:16 EDTACTActavis COPD drug Daliresp gets Paragraph 4 challenge
Subscribe for More Information
08:05 EDTACTActavis price target raised to $348 from $328 at Leerink
Subscribe for More Information
08:04 EDTACTActavis potential acquisition Rhythm initiates Phase 2b study of relamorelin
Subscribe for More Information
07:34 EDTACTActavis initiates Phase 2b clinical trial of relamorelin
Subscribe for More Information
April 7, 2015
08:11 EDTMS, GSGoldman Sachs, Morgan Stanley estimates raised at Susquehanna
Susquehanna raised its estimates for both Goldman Sachs (GS) and Morgan Stanley (MS) to reflect a strong quarter for FICC driven by interest rate and currency volatility and more stable credit markets as well as better I&L. Susquehanna maintains Neutral ratings on both Goldman Sachs and Morgan Stanley shares.
April 6, 2015
18:01 EDTGSCanada GEN Investment to sell 73.39M shares of General Motors to Goldman Sachs
Subscribe for More Information
April 5, 2015
14:43 EDTACTActavis seeks FDA approval to market generic version of Gilead's Letairis
Actavis (ACT) on Friday, confirmed that it has filed an Abbreviated New Drug Application with the FDA seeking approval to market Ambrisentan Tablets, 5 mg and 10 mg. Actavis' ANDA product is a generic version of Gilead Science's (GILD) Letairis, which is a treatment for pulmonary arterial hypertension. Gilead Sciences and Royalty Pharma Collection Trust filed suit against Actavis on April 1, in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of U.S. Patent number RE42,462. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities. Based on available information, Actavis believes it may be a "first applicant" to file an ANDA for the generic version of Letairis and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity. For the 12 months ending December 31, Letairis had global sales of approximately $595M, according to Gilead.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use